Loading...
Docoh

Brookline Capital Acquisition (BCAC)

Filed: 17 May 21, 4:48pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 12b-25

 

 

Commission File Number: 001-39488

NOTIFICATION OF LATE FILING

 

     

☐  Form 10-K     ☐  Form 20-F    ☐  Form 11-K    ☒  Form 10-Q

☐  Form 10-D     ☐  Form N-SAR    ☐  Form N-CSR

 For Period Ended: March 31, 2021
 ☐  Transition Report on Form 10-K
 ☐  Transition Report on Form 20-F
 ☐  Transition Report on Form 11-K
 ☐  Transition Report on Form 10-Q
 

☐  Transition Report on Form N-SAR

 For the Transition Period Ended:

 

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

      

 

PART I

REGISTRANT INFORMATION

 

Full name of registrant  Brookline Capital Acquisition Corp.
Former name if applicable  
Address of principal executive office  600 Lexington Avenue, 33rd Floor
City, state and zip code  New York, NY 10022

PART II

RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 

☒    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III

NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

The compilation, dissemination and review by Brookline Capital Acquisition Corp. (the “Company”) of the information required to be presented in the Form 10-Q for the relevant period, particularly in light of the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies issued by the Securities and Exchange Commission on April 12, 2021, has imposed time constraints that have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant. The Company expects to file the Form 10-Q on or before the 5th calendar day following the prescribed due date.

PART IV

OTHER INFORMATION

 

(1)

   Name and telephone number of person to contact in regard to this notification
   Dr. Samuel Wertheimer    646    643-6716
   (Name)        (Area Code)        (Telephone Number)

(2)

 

    

  

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).    ☒  Yes    ☐  No

 

(3)

   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?    ☐  Yes    ☒  No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Brookline Capital Acquisition Corp.

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: May 17, 2021    

/s/ Dr. Samuel Wertheimer

  By:  Dr. Samuel Wertheimer
  Title:  Chief Executive Officer and Chairman of the Board of Directors